PET Imaging of Tau Pathology and Relationship to Amyloid,Longitudinal MRI,and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI)
Restricted accessResearch articleFirst published online September 18, 2017
PET Imaging of Tau Pathology and Relationship to Amyloid,Longitudinal MRI,and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI)
Adults with Down syndrome (DS) represent an enriched population for the development of Alzheimer’s disease (AD), which could aid the study of therapeutic interventions, and in turn, could benefit from discoveries made in other AD populations.
Objectives:
1) Understand the relationship between tau pathology and age, amyloid deposition, neurodegeneration (MRI and FDG PET), and cognitive and functional performance; 2) detect and differentiate AD-specific changes from DS-specific brain changes in longitudinal MRI.
Methods:
Twelve non-demented adults, ages 30 to 60, with DS were enrolled in the Down Syndrome Biomarker Initiative (DSBI), a 3-year, observational, cohort study to demonstrate the feasibility of conducting AD intervention/prevention trials in adults with DS. We collected imaging data with 18F-AV-1451 tau PET, AV-45 amyloid PET, FDG PET, and volumetric MRI, as well as cognitive and functional measures and additional laboratory measures.
Results:
All amyloid negative subjects imaged were tau-negative. Among the amyloid positive subjects, three had tau in regions associated with Braak stage VI, two at stage V, and one at stage II. Amyloid and tau burden correlated with age. The MRI analysis produced two distinct volumetric patterns. The first differentiated DS from normal (NL) and AD, did not correlate with age or amyloid, and was longitudinally stable. The second pattern reflected AD-like atrophy and differentiated NL from AD. Tau PET and MRI atrophy correlated with several cognitive and functional measures.
Conclusions:
Tau accumulation is associated with amyloid positivity and age, as well as with progressive neurodegeneration measurable using FDG and MRI. Tau correlates with cognitive decline, as do AD-specific hypometabolism and atrophy.
HeadE, PowellD, GoldBT, SchmittFA (2012) Alzheimer’s disease in Down syndrome. Eur J Neurodegener Dis1, 353–364.
2.
HofPR, BourasC, PerlDP, SparksDL, MehtaN, MorrisonJH (1995) Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down’s syndrome. Quantitative regional analysis and comparison with Alzheimer’s disease. Arch Neurol52, 379–391.
3.
MannDM, YatesPO, MarcyniukB, RavindraCR (1986) The topography of plaques and tangles in Down’s syndrome patients of different ages. Neuropathol Appl Neurobiol12, 447–457.
4.
NessS, RafiiM, AisenP, KramsM, SilvermanW, ManjiH (2012) Down’s syndrome and Alzheimer’s disease: Towards secondary prevention. Nat Rev Drug Discov11, 655–656.
5.
RafiiMS, WishnekH, BrewerJB, DonohueMC, NessS, MobleyWC, AisenPS, RissmanRA (2015) The Down Syndrome Biomarker Initiative (DSBI) Pilot: Proof of concept for deep phenotyping of Alzheimer’s disease biomarkers in Down syndrome. Front Behav Neurosci9, 239.
6.
MatthewsDC, LukicAS, AndrewsRD, MarendicB, BrewerJ, RissmanRA, MosconiL, StrotherSC, WernickMN, MobleyWC, NessS, SchmidtME, RafiiMS (2016) Dissociation of Down syndrome and Alzheimer’s disease effects with imaging. Alzheimers Dement (N Y)2, 69–81.
7.
LoweVJ, CurranG, FangP, LiesingerAM, JosephsKA, ParisiJE, KantarciK, BoeveBF, PandeyMK, BruinsmaT, KnopmanDS, JonesDT, PetrucelliL, CookCN, Graff-RadfordNR, DicksonDW, PetersenRC, JackCRJr, MurrayME (2016) An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun4, 58.
FormanMS, ZhukarevaV, BergeronC, ChinSS, GrossmanM, ClarkC, LeeVM, and TrojanowskiJQ (2002) Signature tau neuropathology in gray and white matter of corticobasal degeneration. Am J Pathol160, 2045–2053.
10.
NelsonLD, SiddarthP, KepeV, ScheibelKE, HuangSC, BarrioJR, and SmallGW (2011) Positron emission tomography of brain β-amyloid and τ levels in adults with Down Syndrome. Arch Neurol68, 768–774.
11.
StrotherSC, AndersonJ, HansenLK, KjemsU, KustraR, SidtisJ, FrutigerS, MuleyS, LaconteS, RottenbergD (2002) The quantitative evaluation of functional neuroimaging experiments: The NPAIRS data analysis framework. Neuroimage15, 747–771.
12.
StrotherSC, OderA, SpringR, GradyC (2010) The NPAIRS Computational Statistics Framework for Data Analysis in Neuroimaging. Proceedings of COMPSTAT pp. 111–120.
13.
AshburnerJ (2007) A fast diffeomorphic image registration algorithm. Neuroimage38, 95–113.
14.
SchöllM, LockhartSN, SchonhautDR, O’NeilJP, JanabiM, OssenkoppeleR, BakerSL, VogelJW, FariaJ, SchwimmerHD, RabinoviciGD, JagustWJ (2016) PET imaging of tau deposition in the aging human brain. Neuron89, 971–982.
FaulF, ErdfelderE, LangAG, BuchnerA (2007) G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods39, 175–191.
21.
DrzezgaA (2009) Diagnosis of Alzhiemer’s disease with [18F]PET in mild and asymptomatic stages. Behav Neurol21, 101–115.
22.
MosconiL, TsuiWH, De SantiS, LiJ, RusinekH, ConvitA, LiY, BoppanaM, de LeonMJ (2005) Reduced hippocampal metabolism in MCI and AD: Automated FDG-PET image analysis. Neurology64, 1860–1867.
23.
JohnsonKA, SchultzA, BetenskyRA, BeckerJA, SepulcreJ, RentzD, MorminoE, ChhatwalJ, AmariglioR, PappK, MarshallG, AlbersM, MauroS, PepinL, AlverioJ, JudgeK, PhiliossaintM, ShoupT, YokellD, DickersonB, Gomez-IslaT, HymanB, VasdevN, SperlingR (2016) Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol79, 110–119.
24.
GonzalezLM, AndersonVA, WoodSJ, MitchellLA, HeinrichL, HarveyAS (2008) The Observer Memory Questionnaire-Parent Form: Introducing a new measure of everyday memory for children. J Int Neuropsychol Soc14, 337–342.
25.
CarducciF, OnoratiP, CondoluciC, De GennaroG, QuaratoPP, PieralliniA, SaráM, MianoS, CorniaR, AlbertiniG (2013) Whole-brain voxel-based morphmetry study of children and adolescents with Down syndrome. Funct Neurol28, 19–28.
26.
Smigielska-KuziaJ, BoćkowskiL, SobaniecW, SendrowskiK, OlchowikB, CholewaM, LukasiewiczA, LebkowskaU (2011) A volumetric magnetic resonance imaging study of brain structures in children with Down syndrome. Neurol Neurochir Pol45, 363–369.
27.
ThompsonPM, MegaMS, WoodsRP, ZoumalanCI, LindshieldCJ, BlantonRE, MoussaiJ, HolmesCJ, CummingsJL, TogaAW (2001) Cortical change in Alzheimer’s disease detected with a disease-specific population-based brain atlas. Cereb Cortex11, 1–16.
28.
DukartJ, MuellerK, VillringerA, KherifF, DraganskiB, FrackowiakR, SchroeterML, Alzheimer’s Disease Neuroimaging Initiative (2013) Relationship between imaging biomarkers, age, progression and symptom severity in Alzheimer’s disease. Neuroimage Clin3, 84–94.
29.
OssenkoppeleR, SchonhautDR, SchöllM, LockhartSN, AyaktaN, BakerSL, O’NeilJP, JanabiM, LazarisA, CantwellA, VogelJ, SantosM, MillerZA, BettcherBM, VosselKA, KramerJH, Gorno-TempiniML, MillerBL, JagustWJ, RabinoviciGD (2016) Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain139, 1551–1567.
30.
SchwarzAJ, ShcherbininS, MillerBB, YuP, NavitskyM, DicksonJ, JoshiAD, DevousMDSr, MintunMA (2015) Hippocampal sparing and limbic predominant tau subtypes of Alzheimer’s disease determinedusing [18F]-AV-1451 PET imaging. Alzheimers Dement11, P144–P145.
31.
Sepulveda-FallaD, MatschkeJ, BernreutherC, HagelC, PuigB, VillegasA, GarciaG, ZeaJ, Gomez-MancillaB, FerrerI, LoperaF, GlatzelM (2011) Deposition of hyperphosphorylated tau in cerebellum of PS1 E280A Alzheimer’s disease. Brain Pathol21, 452–463.
SchwarzCG, SenjemML, GunterJL, TosakulwongN, WeigandSD, KempBJ, SpychallaAJ, VemuriP, PetersenRC, LoweVJ, JackCRJr (2017) Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. Neuroimage144, 113–127.
34.
ChenK, RoontivaA, ThiyyaguraP, LeeW, LiuX, AyutyanontN, ProtasH, LuoJL, BauerR, ReschkeC, BandyD, KoeppeRA, FleisherAS, CaselliRJ, LandauS, JagustWJ, WeinerMW, ReimanEM, Alzheimer’s Disease Neuroimaging Initiative (2015) Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region. J Nucl Med56, 560–566.
35.
Mukaetova-LadinskaEB, HarringtonCR, RothM, WischikCM (1993) Biochemical and anatomical redistribution of tau protein in Alzheimer’s disease. Am J Pathol143, 565–578.
36.
KhatoonS, Grundke-IqbalI, IqbalK (1994) Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer disease and control brains. FEBS Lett351, 80–84.
